The combined pharmacological inhibition of FSP1 and GPX4 might be an effective strategy for sensitizing cancer cells, particularly cancer cells that are not sensitive to a GPX4 inhibitor alone, to ferroptosis-inducing chemotherapeutics. This evidence concerns the gene GPX4 and cancer.